Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence
- 1 October 2020
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 79 (10) , 1327-1332
Abstract
Objectives Tumour necrosis factor inhibitors (TNFis) have been suggested to slow radiographic progression in patients with ankylosing spondylitis. However, limitations such as variations in disease activity, complex drug administration and short follow-up duration make it difficult to determine the effect of TNFis on radiographic progression. The aim of the study was to investigate whether long-term treatment with TNFis can reduce radiographic progression in patients with ankylosing spondylitis using 18-year longitudinal real-world data. Methods This retrospective study was conducted between January 2001 and December 2018 at a single centre. Among the 1280 patients whose electronic medical records were reviewed, data of 595 patients exposed to TNFis at least once were included. Among them, time intervals of TNFi exposure or non-exposure were determined in 338 patients (‘on the TNFis’ or ‘off the TNFis’ intervals, respectively). The difference in the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) change rate between ‘on the TNFis’ and ‘off the TNFis’ intervals was investigated. Results We obtained 2364 intervals of 338 patients (1281 ‘on the TNFis’ and 1083 ‘off the TNFis’ intervals). In the marginal structural model for inverse probability of treatment weighting, the change rate of mSASSS significantly decreased with the use of TNFis (β=−0.112, p=0.004), and the adjusted mSASSS changes were 0.848 and 0.960 per year during ‘on the TNFis’ and ‘off the TNFis’ intervals, respectively. Conclusion Compared with treatment without TNFis, treatment with TNFis slowed radiologic progression significantly.Keywords
This publication has 26 references indexed in Scilit:
- Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitisAnnals of the Rheumatic Diseases, 2014
- Baseline radiographic damage, elevated acute‐phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritisArthritis & Rheumatism, 2011
- Radiographic severity of ankylosing spondylitis is associated with polymorphism of the large multifunctional peptidase 2 gene in the Spondyloarthritis Research Consortium of Canada cohortArthritis & Rheumatism, 2011
- Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 yearsArthritis Research & Therapy, 2009
- Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitisArthritis & Rheumatism, 2008
- Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanerceptArthritis & Rheumatism, 2008
- Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohortAnnals of the Rheumatic Diseases, 2007
- Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor α antibody infliximabAnnals of the Rheumatic Diseases, 2005
- Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring systemAnnals of the Rheumatic Diseases, 2005
- Evaluation of Diagnostic Criteria for Ankylosing SpondylitisArthritis & Rheumatism, 1984